Article
The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection.
Hepatology (Baltimore, Md.) - 1 Sept 2002
Barnes Eleanor, Harcourt Gillian, Brown Dave, Lucas Michaela, Phillips Rodney, Dusheiko Geoffrey, Klenerman Paul
Abstract excerpt
Hepatitis C virus (HCV) readily sets up a persistent infection and is a major cause of liver disease worldwide. Interferon alfa and ribavirin therapy lead to sustained clearance of virus in 31% to 64% of patients with type 1 and non-type 1 genotypes, respectively. It is not clear to what extent these drugs act directly to reduce HCV replication, or indirectly via host immune responses, and what evoked immune...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
